上 市 公 司 公 司 研 究 / 公 司 点 评 证 券 研 究 报 告 | 报告原因：有业绩公布需要点评 | | --- | | 增持（维持） | | 市场数据： | 2026 年 03 月 20 日 | | --- | --- | | 收盘价（元） | 20.95 | | 一年内最高/最低（元） | 46.98/11.35 | | 市净率 | 4.0 | | 股息率%（分红/股价） | 0.72 | | 流通 A 股市值（百万元） | 1,688 | | 上证指数/深证成指 | 3,957.05/13,866.20 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 12 月 31 日 | | --- | --- | | 每股净资产（元） | 5.61 | | 资产负债率% | 22.90 | | 总股本/流通 A 股（百万） | 85/81 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： -50% 0% 50% 100% 150% 200% 03-20 04-20 05-20 06-20 07-20 08-20 09-20 10- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company achieved a revenue of 362 million yuan in 2025, representing a year-on-year growth of 16.63%, and a net profit attributable to shareholders of 42.13 million yuan, which is a significant increase of 222.30% year-on-year [6] - The company is focusing on expanding its high-end product matrix through new product launches in chromatography and mass spectrometry, which is expected to accelerate business growth [5] - The overall gross margin improved to 65.04%, with a notable increase in the chromatography series gross margin by 4.12 percentage points to 58.55% [6] - The company plans to implement a simplified procedure for a targeted stock issuance to raise funds, which could facilitate efficient financing of less than 100 million yuan [6] Financial Performance Summary - In 2025, the company reported a net cash flow from operating activities of 50.52 million yuan, up 80.52% year-on-year [6] - The company’s four core scientific instrument series showed robust growth, with the sample pretreatment series leading with a revenue of 70.86 million yuan, a year-on-year increase of 23.27% [6] - The domestic market revenue reached 284 million yuan, growing by 18.40% year-on-year, while overseas revenue was 77.79 million yuan, up 10.59% [6] - The company’s earnings per share (EPS) for 2025 is projected at 0.49 yuan, with a forecasted PE ratio of 45.55 [8] Future Outlook - The company is expected to continue its growth trajectory with projected net profits of 60 million yuan in 2026, 80 million yuan in 2027, and 102 million yuan in 2028, corresponding to a PE ratio of 32, 24, and 19 respectively [8] - The company is actively expanding into strategic emerging sectors such as biomanufacturing, nuclear industry, new materials, and new energy, with significant customer acquisition success [6] - The company is also focusing on R&D and product breakthroughs across its major product lines, including the development of an automated nitrogen analyzer and a new generation microwave digestion instrument [7]